Home / Business News (page 4)

Business News

Amgen Enters Multi-Target Collaboration with Abilita Bio for its Membrane Protein Technology

SAN DIEGO, Feb. 13, 2019 /PRNewswire/ — Abilita Bio, Inc. announced today that it has entered into a multi-target research collaboration agreement with Amgen, a world leader in biotechnology. Under the terms of the agreement, Abilita Bio will leverage its proprietary Enabled Membrane Protein (EMP™) technology platform to support Amgen’s …

Read More »

Johnson & Johnson to Acquire Robotic Surgery Company Auris Health for $3.4 Billion

New Brunswick, NJ – February 13, 2019 – Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ), today announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, in the aggregate, …

Read More »

Boehringer Ingelheim and IBM Collaborate to Explore Use of Blockchain Technology in Clinical Trials

BURLINGTON, Ontario and MARKHAM, Ontario, Feb. 12, 2019 /PRNewswire/ — Boehringer Ingelheim (Canada) Ltd. and IBM Canada (NYSE: IBM) announced today at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology in clinical trials. This collaboration underscores Boehringer …

Read More »

AbbVie Partners with Teneobio to Develop BCMA Bispecific Antibody for Treatment of Multiple Myeloma

NORTH CHICAGO, Ill. and MENLO PARK, Calif., Feb. 11, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV),  Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma. B-cell maturation antigen (BCMA) has emerged as an …

Read More »

TamRx Launches to Develop Pipeline of Immuno-Oncology Products for Treatment of Cancers

CLEVELAND–(BUSINESS WIRE)–BioMotiv, a drug development accelerator associated with The Harrington Project for Discovery & Development, and researchers from Rutgers, The State University of New Jersey, today announced the formation of a new biotech start-up, TamRx. The new company will focus on the development of a novel family of small molecule inhibitors designed …

Read More »

Evotec and Galapagos Enter Collaboration Focused on a Novel Target in the Field of Fibrosis

Mechelen, Belgium, and Hamburg, Germany; 7 February 2019, 7.30 CET – Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809), and Galapagos NV (Euronext & NASDAQ: GLPG) today announced a global collaboration focused on a novel target for fibrosis and other indications. The collaboration concerns a small-molecule program, currently in …

Read More »

Xencor and Genentech Partner to Develop and Commercialize Novel IL-15 Immune Activating Cytokines

MONROVIA, Calif., Feb. 5, 2019 /PRNewswire/ — Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, today announced it has entered into a research and license agreement with Genentech, a member of the Roche Group, to develop and commercialize novel …

Read More »

Merck KGaA and GSK Partner to Jointly Develop and Commercialize Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers

DARMSTADT, Germany, Feb. 5, 2019 /PRNewswire/ — Merck KGaA, Darmstadt, Germany, a leading science and technology company and GSK, a science-led global healthcare company, today announced that the companies have entered into a global strategic alliance to jointly develop and commercialize M7824 (bintrafusp alfa*). M7824 is an investigational bifunctional fusion …

Read More »

Argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology

Breda, the Netherlands / Ghent, Belgium & San Diego – argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme’s ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx …

Read More »

Alexion Collaborates with Caelum Biosciences to Develop Targeted Therapy for Light Chain Amyloidosis

BOSTON & NEW YORK–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Caelum Biosciences today announced a collaboration to develop CAEL-101 for light chain (AL) amyloidosis. CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis. AL amyloidosis is …

Read More »